Skip to content
TrialScanner

NCT02026063

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

Phase 3CompletedLXRXLead

Registry record

Lead sponsor
Lexicon Pharmaceuticals
Conditions
Carcinoid Syndrome
Primary completion
Sep 12, 2018Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02026063 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02026063: Telotristat Etiprate... | TrialScanner